Un caso clínico de penfigoide ampolloso inducido por vildagliptina

González Arnáiz, Elena; Olmos Nieva, Claudia; Ariadel Cobo, Diana; Alejo Ramos, Mirian; Ballesteros Pomar, María D.
Endocrinol. diabetes nutr. (Ed. impr.) ; 67(9): 613-614, nov. 2020. ilus
Artigo Espanhol | IBECS (Espanha) | ID: ibc-197344

Documentos relacionados

  1. Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients.
  2. Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid.
  3. Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis.
  4. New-onset bullous pemphigoid after inactivated Covid-19 vaccine: Synergistic effect of the Covid-19 vaccine and vildagliptin.
  5. Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients.
  6. Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.
  7. The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study.
  8. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis.
  9. Vildagliptin-induced bullous pemphigoid.
  10. Gliptin-induced bullous pemphigoid: withdrawal of gliptin allows for faster control of the disease